Accredited Symposium: Neuroradiology

Eisai co-Developed Accredited Symposium:

The Critical Role of Imaging in Alzheimer’s and ARIA Diagnosis

Friday, April 17 | 12:15 PM – 1:15 PM EDT | Le Westin Montréal

The goal of this accredited symposium is to provide delegates with an in-depth learning opportunity in the field of neuroradiology. Delegates will learn about the critical role of imaging in the diagnosis of Alzheimer’s disease and amyloid-related imaging abnormalities (ARIA), a common side effect of new anti-amyloid therapies. Magnetic Resonance Imaging (MRI) is the central tool for monitoring ARIA, allowing clinicians to manage treatment safely. This symposium will discuss the recent evidence on ARIA, guidance from leading experts, as well as resources and management tools to support implementation of new disease modifying treatments in Canadian practices.

The 45-minute session will be followed by a 15-minute question and answer segment with the audience.

This session is included with CAR 2026 registration. Lunch will be provided.

Target Audience

This symposium is targeted for radiologists and trainees with an interest in neuroradiology, who are particularly engaged in imaging neurodegenerative diseases such as Alzheimer’s disease and associated dementia diagnoses.

Needs Assessment

This accredited symposium was developed in response to a comprehensive assessment of CPD interests among Canadian Association of Radiologists (CAR) members, which identified a strong need for advanced education in neuroradiology. Expert consultations and input from the ASM planning committee further confirmed the importance of equipping radiologists with the knowledge and tools to diagnose Alzheimer’s disease, recognize and manage amyloid-related imaging abnormalities (ARIA), and implement new anti-amyloid therapies safely and effectively in Canadian clinical practice.

Learning Objectives

At the end of this symposium, delegates will be able to:

1. Describe the current diagnostic criteria for Alzheimer’s Disease and summarize updates on treatment options available in Canada.
2. Identify and report Amyloid-Related Imaging Abnormalities (ARIA) to ensure appropriate patient safety management.
3. Analyze strategies for real-world implementation of Alzheimer’s therapies and propose approaches to build capacity within clinical settings.

CanMEDS

Medical Expert, Scholar, Professional, Leader, Collaborator, Health Advocate

Accreditation and Designation Statement

This symposium was co-developed with Eisai Inc and was planned to achieve scientific integrity, objectivity, and balance. This accredited symposium has been approved for a maximum of 1.0 credit, under Section 1 (Group Learning), as defined MOC program of the Royal College and approved by the CAR.

Participants should only claim the credits commensurate with the extent of their participation in the activity.